Lineage Cell Therapeutics's gross profit for the
three
months ended in Sep. 2024 was $3.74 Mil. Lineage Cell Therapeutics's gross profit for the trailing twelve months (TTM) ended in Sep. 2024 was $8.28 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Lineage Cell Therapeutics's Gross Profit
For the Biotechnology subindustry, Lineage Cell Therapeutics's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lineage Cell Therapeutics's Gross Profit Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lineage Cell Therapeutics's Gross Profit distribution charts can be found below:
* The bar in red indicates where Lineage Cell Therapeutics's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $8.28 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Lineage Cell Therapeutics had a gross margin of 98.99% for the quarter that ended in Sep. 2024 => Durable competitive advantage
Lineage Cell Therapeutics Gross Profit Related Terms
Thank you for viewing the detailed overview of Lineage Cell Therapeutics's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LCTX has been successfully added to your 